Clinical Trial

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Study acronym: DOMENICA
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial cancer.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2022-01-20; most recent amendment 2025-11-27.
Status change: Recruiting → Active, Not Recruiting 2025-07-09
Status change: Not Yet Recruiting → Recruiting 2022-06-14
Trial Details
NCT Number NCT05201547
Lead Sponsor ARCAGY/ GINECO GROUP
Collaborators: GlaxoSmithKline
Conditions Endometrial Cancer
Enrollment 260 participants
Start Date 2022-04-15
Primary Completion 2026-04 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-04